| Literature DB >> 35133481 |
Charlie Osborne1, Daniel Lewis2, Ben Dixon3, Carmela Caputo4, Alison Magee5, Kanna Gnanalingham2, Yi Yuen Wang6,7,8.
Abstract
BACKGROUND: T ranssphenoidal surgery (TSS) is the standard approach for resection of pituitary lesions. Historically, this has utilized the microscopic approach (mTSS); however, the past decade has seen widespread uptake of the endoscopic approach (eTSS). The purported benefits of this include improved visualization and illumination, resulting in improved surgical and endocrinological patient outcomes. It is also believed that eTSS results in fewer post-operative nasal symptoms compared to mTSS; however, few papers have directly compared these groups.Entities:
Keywords: Endoscopic; Microscopic; Nasal symptoms; Transsphenoidal surgery
Mesh:
Year: 2022 PMID: 35133481 PMCID: PMC9160117 DOI: 10.1007/s00701-022-05138-5
Source DB: PubMed Journal: Acta Neurochir (Wien) ISSN: 0001-6268 Impact factor: 2.816
Population characteristics and pathological data stratified by surgical approach
| Factor | Total (%) | Microscopic TSS | Uninostril eTSS | Binostril eTSS | ||
|---|---|---|---|---|---|---|
| 136 | 25 | 74 | 37 | |||
Median age, years (IQR) | 57.7 (44.5–70.0) | 54.4 (47.9–66.3) | 59.4 (43.1–68.5) | 57.0 (44.6–73.7) | 0.99 | |
| Gender | Male | 68 (50) | 11 (44) | 37 (50) | 20 (54) | 0.74 |
| Female | 68 (50) | 14 (66) | 37 (50) | 17 (46) | ||
| Histology | NFPA | 71 (52) | 9 (36) | 46 (62) | 16 (43) | |
| Functioning (ACTH/GH/PRL) | 26 (19) | 5 (20) | 14 (19) | 7 (19) | ||
| Meningioma | 6 (4) | 0 (0) | 1 (1) | 5 (14) | ||
| RCC | 14 (10) | 4 (16) | 8 (11) | 2 (5) | ||
| Craniopharyngioma | 5 (4) | 2 (8) | 1 (1) | 2 (5) | ||
| Other* | 14 (10) | 5 (20) | 4 (5) | 5 (14) | ||
| Tumour size | Macroadenoma | 83 (61) | 11 (44) | 52 (70) | 20 (54) | 0.08 |
| Microadenoma | 14 (10) | 3 (12) | 8 (11) | 3 (8) | ||
| Non-adenoma | 39 (29) | 11 (44) | 14 (19) | 14 (38) | ||
| Use of septal flap | Yes | 23 (17) | 4 (16) | 4 (5) | 15 (41) | |
| Prior endonasal surgery | Yes | 3 (2) | 0 (0) | 3 (4) | 0 (0) | 0.28 |
| Intra-op CSF leak | Present | 49 (36) | 5 (20) | 29 (39) | 15 (41) | 0.18 |
Absolute number and percentage shown (in brackets). p value calculated using Kruskal–Wallis test with post hoc analysis of pairwise comparisons using the Bonferroni method. Differences in patient gender, tumour histology, tumour size, use of nasoseptal flap and intra-operative CSF leak determined using Pearson’s chi-square test
ACTH, corticotropinoma; eTSS, endoscopic transsphenoidal surgery; GH, somatotropinoma; IQR, interquartile range; NFPA, non-functioning pituitary adenoma; PRL, prolactinoma; RCC, Rathke’s cleft cyst; eTSS, endoscopic transsphenoidal surgery
*Other = apoplexy; cholesterol granuloma; chordoma; lymphocytic hypophysitis; lymphoma; myeloma; Wegener’s granulomatosis
Fig. 1Total GNPI score changes over time stratified by surgical approach. Median and interquartile range of total GNPI score at each time point shown. a Change in total GNPI score over time for all 136 patients across all surgical approaches. Total GNPI scores were significantly higher than pre-treatment scores at post-operative day 1, day 3 and 1–2 weeks post-operatively and were significantly lower than pre-treatment scores at 6 months and 12 months post-treatment (mixed-effects model). **p ≤ 0.01; ***p ≤ 0.001. b Change in total GNPI score stratified by surgical approach. p value for microscopic TSS/binostril eTSS approach is shown and represents difference in GNPI score compared to uninostril eTSS approach at each time point. p value calculated using Kruskal–Wallis test with post hoc analysis of pairwise comparisons using the Bonferroni method. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. eTSS, endoscopic transsphenoidal surgery
Fig. 2Total GNPI score changes over time stratified by surgical approach. Non-functioning pituitary adenoma (NFPA, n = 71) subgroup only. Median and interquartile range of total GNPI score at each time point shown. a Change in total GNPI score over time for all NFPA patients across all surgical approaches. Total GNPI scores within the subgroup of NFPA were significantly higher than pre-treatment scores at post-operative day 1 and day 3 and significantly lower than pre-treatment scores at 12 months post-treatment (mixed-effects model, ***p < 0.001). b Change in total GNPI score stratified by surgical approach. At post-operative day 1, the eTSS-uni group demonstrated lower GNPI scores compared to the mTSS group (median GNPI 16 vs 32) and eTSS-bi group (median GNPI 16 vs 33) but these results did not reach statistical significance (Kruskal–Wallis test with post hoc analysis of pairwise comparisons using the Bonferroni method). eTSS, endoscopic transsphenoidal surgery
Fig. 3Total GNPI score changes over time stratified by adenoma functional status. Median and interquartile range of total GNPI score at each time point shown. p value represents difference in total GNPI score between non-functioning/functioning tumours at each time point. p value calculated using Mann–Whitney U test. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. ACTH, corticotropinoma; GH, somatotropinoma; NFPA, non-functioning pituitary adenoma; PRL, prolactinoma
Ordinal logistic regression to evaluate the effect of each parameter on post-operative day 1 and day 3 GNPI score (N = 136)
| Variable | Day 1 GNPI | Day 3 GNPI | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% OR | OR | 95% OR | ||||
| Age, years | |||||||
| Gender | Female | 1.21 | 0.62, 2.36 | 0.57 | |||
| Pre-treatment GNPI | |||||||
| Approach base: Microscopic | Uninostril eTSS | 1.123 | 0.51, 2.97 | 0.64 | |||
| Binostril eTSS | 1.09 | 0.42, 2.79 | 0.86 | 2.01 | 0.79, 5.10 | 0.14 | |
| Histology base: NFPA | Functioning (ACTH/GH/PRL) | 0.48 | 0.18, 1.28 | 0.14 | 0.84 | 0.30, 2.31 | 0.74 |
| Meningioma | 1.34 | 0.13, 13.4 | 0.80 | 1.51 | 0.19, 12.5 | 0.70 | |
| RCC | 0.31 | 0.06, 1.59 | 0.16 | 0.78 | 0.16, 3.66 | 0.75 | |
| Craniopharyngioma | 0.32 | 0.04, 2.72 | 0.29 | 0.66 | 0.09, 5.15 | 0.70 | |
| Other* | 0.40 | 0.08, 2.10 | 0.28 | ||||
| Tumour size base: microadenoma | Macroadenoma | 0.32 | 0.08, 1.20 | 0.09 | 0.74 | 0.21, 2.64 | 0.65 |
| Use of septal flap | Yes | ||||||
| Intra-op CSF leak | Present | 0.70 | 0.33, 1.47 | 0.35 | 0.70 | 0.33, 1.45 | 0.33 |
ACTH, corticotropinoma; eTSS, endoscopic transsphenoidal surgery; GH, somatotropinoma; IQR, interquartile range; NFPA, non-functioning pituitary adenoma; PRL, prolactinoma; RCC, Rathke’s cleft cyst; eTSS, endoscopic transsphenoidal surgery
*Other = apoplexy; cholesterol granuloma; chordoma; lymphocytic hypophysitis; lymphoma; myeloma; Wegener’s granulomatosis